Tharimmune, Inc. (NASDAQ:THAR) Sees Significant Growth in Short Interest

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 63,500 shares, a growth of 17.2% from the January 15th total of 54,200 shares. Currently, 4.4% of the shares of the company are sold short. Based on an average daily volume of 261,400 shares, the short-interest ratio is currently 0.2 days.

Analysts Set New Price Targets

A number of research analysts have issued reports on THAR shares. Rodman & Renshaw started coverage on shares of Tharimmune in a research note on Friday, December 6th. They set a “buy” rating and a $17.00 target price for the company. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th.

Institutional Trading of Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC purchased a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune at the end of the most recent quarter. 1.16% of the stock is currently owned by hedge funds and other institutional investors.

Tharimmune Stock Performance

Shares of THAR stock remained flat at $1.90 during midday trading on Friday. 11,629 shares of the company’s stock were exchanged, compared to its average volume of 38,894. Tharimmune has a one year low of $1.84 and a one year high of $7.46. The business has a 50 day simple moving average of $2.06 and a 200 day simple moving average of $2.40.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).